MX2016000201A - Formulaciones de anticuerpos y metodos. - Google Patents

Formulaciones de anticuerpos y metodos.

Info

Publication number
MX2016000201A
MX2016000201A MX2016000201A MX2016000201A MX2016000201A MX 2016000201 A MX2016000201 A MX 2016000201A MX 2016000201 A MX2016000201 A MX 2016000201A MX 2016000201 A MX2016000201 A MX 2016000201A MX 2016000201 A MX2016000201 A MX 2016000201A
Authority
MX
Mexico
Prior art keywords
methods
antibody formulations
formulations
synucleinopathies
prophylaxis
Prior art date
Application number
MX2016000201A
Other languages
English (en)
Spanish (es)
Inventor
Michael Grundman
Patrick Garidel
Andreas Langer
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MX2016000201A publication Critical patent/MX2016000201A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
MX2016000201A 2013-07-04 2014-07-03 Formulaciones de anticuerpos y metodos. MX2016000201A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361843011P 2013-07-04 2013-07-04
US201461979886P 2014-04-15 2014-04-15
PCT/IB2014/062806 WO2015001504A2 (en) 2013-07-04 2014-07-03 Antibody formulations and methods

Publications (1)

Publication Number Publication Date
MX2016000201A true MX2016000201A (es) 2016-05-31

Family

ID=51355583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000201A MX2016000201A (es) 2013-07-04 2014-07-03 Formulaciones de anticuerpos y metodos.

Country Status (17)

Country Link
US (2) US10513555B2 (enExample)
EP (2) EP3016677B1 (enExample)
JP (3) JP6404338B2 (enExample)
KR (1) KR20160030247A (enExample)
CN (1) CN105492019B (enExample)
AU (1) AU2014285719A1 (enExample)
CA (1) CA2917097C (enExample)
CL (1) CL2015003801A1 (enExample)
CU (2) CU20170039A7 (enExample)
ES (1) ES2704440T3 (enExample)
IL (1) IL243425A0 (enExample)
MX (1) MX2016000201A (enExample)
PE (1) PE20160868A1 (enExample)
PH (1) PH12015502788A1 (enExample)
RU (1) RU2016103079A (enExample)
SG (1) SG11201510601TA (enExample)
WO (1) WO2015001504A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107880123A (zh) 2011-10-28 2018-04-06 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
AU2013211874B2 (en) 2012-01-27 2017-11-02 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017027861A1 (en) 2015-08-13 2017-02-16 Amgen Inc. Charged depth filtration of antigen-binding proteins
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
CN105127166A (zh) * 2015-09-29 2015-12-09 中国华能集团清洁能源技术研究院有限公司 行走组件及具有其的光伏组件清洁装置
HRP20210945T1 (hr) * 2016-06-27 2021-09-17 Morphosys Ag Formulacije protutijela anti-cd19
US10889635B2 (en) * 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
US20190153102A1 (en) * 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
AU2017434556B2 (en) * 2017-09-28 2024-11-14 F. Hoffmann-La Roche Ag Dosing regimes for treatment of synucleinopathies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
JP6831861B2 (ja) 2019-01-25 2021-02-17 株式会社Ｇｒｉｎ 歯科用測定器具、測定方法、及びアタッチメント器具
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
EP3786174A1 (en) * 2019-08-27 2021-03-03 Ichnos Sciences SA Methods for antibody purification
GB2587228B (en) * 2019-09-20 2021-10-27 Protein Ark Ltd Biological sample purification apparatus, use of the same, and systems comprising the same
EP4185612A4 (en) 2020-07-23 2024-12-25 Othair Prothena Limited Anti-abeta antibodies
TW202227131A (zh) 2020-09-10 2022-07-16 愛爾蘭商普羅佘納生物科技有限公司 帕金森氏症之治療
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
WO2023041524A2 (en) 2021-09-16 2023-03-23 H. Lundbeck A/S Compositions and methods for treating synucleinopathies

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
ATE216590T1 (de) 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
BR0007956A (pt) 1999-02-05 2002-04-09 Samsung Electronics Co Ltd Método de recuperação de textura por imagem e equipamento para essa finalidade, e meio legìvel por computador
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
ES2314227T7 (es) 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
WO2004039234A2 (en) 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101235658B1 (ko) 2004-11-10 2013-02-21 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Ｃｈｏ 세포에 대한 세포 뱅킹 전략을 최적화하기 위한 유동 세포측정 분석의 용도
WO2007011907A2 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
EP1963367A4 (en) * 2005-12-06 2009-05-13 Amgen Inc POLISHING STEPS IN MULTI-STAGE PROTEIN PURIFICATION TREATMENTS
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
KR20100015363A (ko) 2007-03-02 2010-02-12 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 단백질 생산의 개선
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
NZ580553A (en) 2007-03-22 2012-05-25 Genentech Inc Apoptotic anti- ige antibodies binding the membrane-bound ige
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
NZ585516A (en) 2007-12-21 2012-07-27 Hoffmann La Roche Anti-cd20 antibody formulation
EA028356B1 (ru) 2007-12-28 2017-11-30 Протена Байосайенсиз Лимитед Лечение и профилактика амилоидоза
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
RU2568831C2 (ru) 2009-07-28 2015-11-20 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20130116413A1 (en) 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
BR112013001062A2 (pt) 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
CA2813747A1 (en) * 2010-10-11 2012-04-19 Chen Wang Processes for purification of proteins
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
US9845327B2 (en) 2011-06-22 2017-12-19 The General Hospital Corporation Treatment of proteinopathies
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
SG10201604104PA (en) * 2011-10-25 2016-07-28 Prothena Therapeutics Ltd Antibody formulations and methods
CN107880123A (zh) 2011-10-28 2018-04-06 普罗典娜生物科学有限公司 识别α‑突触核蛋白的人源化抗体
KR102259829B1 (ko) 2011-10-31 2021-06-03 제넨테크, 인크. 항체 제제
AU2013211874B2 (en) 2012-01-27 2017-11-02 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
EP3016677A2 (en) 2016-05-11
WO2015001504A3 (en) 2015-08-06
CA2917097C (en) 2022-05-03
JP2016534052A (ja) 2016-11-04
KR20160030247A (ko) 2016-03-16
CN105492019A (zh) 2016-04-13
JP2019011339A (ja) 2019-01-24
CU20170039A7 (es) 2017-06-05
CA2917097A1 (en) 2015-01-08
EP3016677B1 (en) 2018-12-19
PH12015502788A1 (en) 2016-03-21
CL2015003801A1 (es) 2016-07-15
AU2014285719A1 (en) 2016-01-21
WO2015001504A2 (en) 2015-01-08
CU20160001A7 (es) 2016-08-31
RU2016103079A (ru) 2017-08-07
JP6854266B2 (ja) 2021-04-07
EP3524264A1 (en) 2019-08-14
JP2021020941A (ja) 2021-02-18
US10513555B2 (en) 2019-12-24
US20150079074A1 (en) 2015-03-19
CN105492019B (zh) 2020-02-11
US20200140534A1 (en) 2020-05-07
PE20160868A1 (es) 2016-09-24
IL243425A0 (en) 2016-03-31
HK1223544A1 (zh) 2017-08-04
SG11201510601TA (en) 2016-01-28
JP6404338B2 (ja) 2018-10-10
ES2704440T3 (es) 2019-03-18

Similar Documents

Publication Publication Date Title
PH12015502788A1 (en) Antibody formulations and methods
MY191169A (en) Anti-fcrh5 antibodies
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2022001105A (es) Anticuerpos anti tigit.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
PH12016501107B1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
PH12018500578A1 (en) Methods of treating inflammatory diseases
WO2019173795A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
IN2014CN04014A (enExample)
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX394633B (es) Profarmacos de antagonista de (s)-1-fenil-2-(piridin-2-il)etanamina (nmda)
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll